123 related articles for article (PubMed ID: 10433027)
1. Antifibrogenic activity of interferon alpha in chronic hepatitis C.
Suou T
J Gastroenterol; 1999 Jun; 34(3):426-7. PubMed ID: 10433027
[No Abstract] [Full Text] [Related]
2. Fibrogenesis serum markers in patients with chronic hepatitis C treated with alpha-IFN.
Fabris P; Marranconi F; Bozzola L; Biasin MR; De Lazzari F; Plebani M; Benedetti P; Tositti G; Pellizzer G; Stecca C; de Lalla F
J Gastroenterol; 1999 Jun; 34(3):345-50. PubMed ID: 10433010
[TBL] [Abstract][Full Text] [Related]
3. Changes of liver fibrosis in chronic hepatitis C patients with no response to interferon-alpha therapy: including quantitative assessment by a morphometric method.
Yagura M; Murai S; Kojima H; Tokita H; Kamitsukasa H; Harada H
J Gastroenterol; 2000; 35(2):105-11. PubMed ID: 10680665
[TBL] [Abstract][Full Text] [Related]
4. Changes in serum tissue inhibitor of matrix metalloproteinase-1 after interferon alpha treatment in chronic hepatitis C.
Mitsuda A; Suou T; Ikuta Y; Kawasaki H
J Hepatol; 2000 Apr; 32(4):666-72. PubMed ID: 10782917
[TBL] [Abstract][Full Text] [Related]
5. Liver stellate cells and aminoterminal peptide of type III procollagen in chronic hepatitis C treated with interferon.
Gabrielli GB; Casaril M; Stanzial AM; Colombari R; Pasino M; Corrocher R
Hepatogastroenterology; 2003; 50(54):2017-21. PubMed ID: 14696456
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal evaluation of a fibrosis index combining MMP-1 and PIIINP compared with MMP-9, TIMP-1 and hyaluronic acid in patients with chronic hepatitis C treated by interferon-alpha and ribavirin.
Trocme C; Leroy V; Sturm N; Hilleret MN; Bottari S; Morel F; Zarski JP
J Viral Hepat; 2006 Oct; 13(10):643-51. PubMed ID: 16970595
[TBL] [Abstract][Full Text] [Related]
7. Alpha-interferon improves liver fibrosis in chronic hepatitis C: clinical significance of the serum N-terminal propeptide of procollagen type III.
Serejo F; Costa A; Oliveira AG; Ramalho F; Batista A; De Moura MC
Dig Dis Sci; 2001 Aug; 46(8):1684-9. PubMed ID: 11508668
[TBL] [Abstract][Full Text] [Related]
8. Controversies in the management of hepatitis C patients with advanced fibrosis and cirrhosis.
Fontana RJ; Everson GT; Tuteja S; Vargas HE; Shiffman ML
Clin Gastroenterol Hepatol; 2004 Mar; 2(3):183-97. PubMed ID: 15017601
[No Abstract] [Full Text] [Related]
9. Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C.
Arthur MJ
Gastroenterology; 2002 May; 122(5):1525-8. PubMed ID: 11984538
[No Abstract] [Full Text] [Related]
10. Changes in histological lesions and serum fibrogenesis markers in chronic hepatitis C patients non-responders to interferon alpha.
Leroy V; De Traversay C; Barnoud R; Hartmann JD; Baud M; Ouzan D; Zarski JP
J Hepatol; 2001 Jul; 35(1):120-6. PubMed ID: 11495029
[TBL] [Abstract][Full Text] [Related]
11. Resistance to alpha interferon therapy in HCV chronic liver disease: role of hepatic fibrosis.
Di Costanzo GG; Ascione A; Lanza AG; De Luca M; Bracco A; Lojodice D; Marsilia GM; Ferbo U
Ital J Gastroenterol; 1996 Apr; 28(3):140-6. PubMed ID: 8789824
[TBL] [Abstract][Full Text] [Related]
12. [Hepatitis C. Saving the liver].
Paul A
MMW Fortschr Med; 1999 Nov; 141(46):16. PubMed ID: 10795138
[No Abstract] [Full Text] [Related]
13. [Chronic hepatitis C viral infection with persistent normal serum alanine aminotransferases].
Huang CX; Bai XF
Zhonghua Gan Zang Bing Za Zhi; 2005 Jan; 13(1):70-1. PubMed ID: 15670508
[No Abstract] [Full Text] [Related]
14. Effect of interferon alpha2b plus ribavirin treatment on selected growth factors in respect to inflammation and fibrosis in chronic hepatitis C.
Anatol P; Robert F; Danuta P
World J Gastroenterol; 2005 Mar; 11(12):1854-8. PubMed ID: 15793880
[TBL] [Abstract][Full Text] [Related]
15. Effect of antiviral therapy on markers of fibrogenesis in patients with chronic hepatitis C.
Nøjgaard C; Johansen JS; Krarup HB; Holten-Andersen M; Møller A; Bendtsen F;
Scand J Gastroenterol; 2003 Jun; 38(6):659-65. PubMed ID: 12825876
[TBL] [Abstract][Full Text] [Related]
16. Soluble adhesion molecules correlate with liver inflammation and fibrosis in chronic hepatitis C treated with interferon-alpha.
Lo Iacono O; García-Monzón C; Almasio P; García-Buey L; Craxí A; Moreno-Otero R
Aliment Pharmacol Ther; 1998 Nov; 12(11):1091-9. PubMed ID: 9845398
[TBL] [Abstract][Full Text] [Related]
17. Reversibility of cirrhosis in chronic hepatitis B.
Malekzadeh R; Mohamadnejad M; Rakhshani N; Nasseri-Moghaddam S; Merat S; Tavangar SM; Sohrabpour AA
Clin Gastroenterol Hepatol; 2004 Apr; 2(4):344-7. PubMed ID: 15067631
[TBL] [Abstract][Full Text] [Related]
18. Treatment rate and factors related to interferon-based treatment initiation for chronic hepatitis C in South Korea.
Lee SS; Jeong SH; Jang ES; Kim YS; Lee YJ; Jung EU; Kim IH; Bae SH; Lee HC
J Med Virol; 2016 Feb; 88(2):275-81. PubMed ID: 26211752
[TBL] [Abstract][Full Text] [Related]
19. Reversal of cirrhosis: evidence-based medicine?
Desmet VJ; Roskams T
Gastroenterology; 2003 Aug; 125(2):629-30; author reply 630-31. PubMed ID: 12891578
[No Abstract] [Full Text] [Related]
20. Serum markers of hepatic fibrogenesis in chronic hepatitis type C treated with alfa-2A interferon.
Gallorini A; Plebani M; Pontisso P; Chemello L; Masiero M; Mantovani G; Alberti A
Liver; 1994 Oct; 14(5):257-64. PubMed ID: 7997085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
